Evidence map›Paper›PMID 28351204›Full record

Trial reportJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists2017

Results From the VISIBILITY Iliac Study: Primary and Cohort Outcomes at 9 Months.

John H Rundback, Patrick Peeters, Jon C George, Michael R Jaff, Peter L Faries

Registry-linked trialOpen access · hybridAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01402700 (Visi-Pro™ Balloon Expandable Iliac Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01402700 nacompletednot on this map

Visi-Pro™ Balloon Expandable Iliac Study (VISIBILITY™ Iliac)

TypeinterventionalSponsorMedtronic EndovascularRan2011 to 2015Enrolled75ConditionsPeripheral Arterial Disease, ClaudicationArmsVisi-Pro™ Balloon Expandable Stent System
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Short-term outcomes of the iCover balloon-expandable covered stent for iliac artery lesions.Diagnostic and interventional radiology (Ankara, Turkey) · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

John H Rundback1 Interventional Institute, Holy Name Medical Center, Teaneck, NJ, USA.
Patrick Peeters2 Imelda Hospital, Bonheiden, Belgium.
Jon C George3 Cardiovascular Medicine, Temple University Hospital, Philadelphia, PA, USA.
Michael R Jaff4 Vascular Center and Vascular Ultrasound Core Laboratory, Massachusetts General Hospital, Boston, MA, USA.
Peter L Faries5 Division of Vascular Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Holy Name Medical Center · USIcahn School of Medicine at Mount Sinai · USImelda Hospital · BEMassachusetts General Hospital · USTemple University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the safety and effectiveness of primary stenting of the common (CIA) or external iliac artery (EIA) using the Visi-Pro Balloon-Expandable Peripheral Stent System for treatment of stenotic, restenotic, or occluded lesions.

methodsBetween 2011 and 2012, 75 patients (mean age 64.2±8.9 years; 46 men) with Rutherford category 2-4 ischemia and atherosclerotic lesions ≤10 cm in length underwent iliac artery stenting at 17 centers in the United States and Europe. The primary outcome of the study was the major adverse event (MAE) rate at 9 months postprocedure [composite of periprocedural death, in-hospital myocardial infarction, clinically driven target lesion revascularization (CD-TLR), and amputation of the treated limb]. Secondary outcomes included 30-day MAE rate, 9-month primary patency, changes in ankle-brachial index (ABI) and the Walking Impairment Questionnaire at 30 days and 9 months postprocedure, device success, and clinically driven target vessel revascularization (CD-TVR) at 30 days and 9 months. Outcomes in specific patient cohorts (ie, gender, stent location, calcification severity, and lesion grade) were analyzed.

resultsEighty-one stents were implanted in 61 CIA and 15 EIA lesions (41 with moderate/severe calcification). The mean lesion treated length was 29.3±13.9 mm. All devices were successfully deployed. MAE occurred in 3 (4.0%) of 75 subjects at 9 months. Primary patency and freedom from CD-TVR at 9 months were both 95.8%. ABI improved from 0.67±0.14 at baseline to 0.94±0.14 and 0.96±0.16 at 30 days and 9-month follow-up, respectively (p<0.001 for both). There were no differences with respect to any of the analyzed patient characteristics, including gender.

conclusionNine-month results of the VISIBILITY Iliac stent study ( ClinicalTrials.gov identifier NCT01402700) demonstrated safety and effectiveness for the treatment of atherosclerotic CIA and EIA lesions with the Visi-Pro stent across all treated cohorts.

Indexed as

Iliac ArteryAgedAmputation, SurgicalAngioplasty, BalloonAnkle Brachial IndexConstriction, PathologicDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateLimb SalvageMaleMiddle AgedPeripheral Arterial DiseaseProspective Studiesballoon-expandable stentclaudicationcommon iliac arteryexternal iliac arteryiliac arteryperipheral artery diseasestent

Identifiers

PMID28351204
PMCPMC5438081
OpenAlexW2594737365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.